Page last updated: 2024-11-12

t-tucb

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID16756850
CHEMBL ID2397148
CHEMBL ID1552108
SCHEMBL ID15612815
SCHEMBL ID4256244
SCHEMBL ID4256246
MeSH IDM000595926

Synonyms (32)

Synonym
bdbm25741
urea-based compound, 22
4-{[4-({[4-(trifluoromethoxy)phenyl]carbamoyl}amino)cyclohexyl]oxy}benzoic acid
smr001339074
MLS002415559
HMS2218A24
CHEMBL2397148
HMS3338J09
trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid
cis-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid
SCHEMBL15612815
SCHEMBL4256244
SCHEMBL4256246
t-tucb
CHEMBL1552108
us9029401, 1686
bdbm158481
bdbm158480
us9029401, 1728 (t-tucb)
CS-0080878
HY-114266
uc-1728
4-[4-[[4-(trifluoromethoxy)phenyl]carbamoylamino]cyclohexyl]oxybenzoic acid
bxv ,
4-{[trans-4-({[4-(trifluoromethoxy)phenyl]carbamoyl}amino)cyclohexyl]oxy}benzoic acid
uc-1728 (t-tucb)
948304-40-3
4-[[trans-4-[[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]cyclohexyl]oxy]benzoic acid
D87163
t-tucbt-tucb
xdvfkczzxogemn-uhfffaoysa-n
AKOS040742799
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency17.78280.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency8.91250.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency5.80240.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)1.06670.00020.59827.0000AID1373457; AID1373459
Cocaine esteraseHomo sapiens (human)IC50 (µMol)10.00000.00582.43306.8000AID1373466
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)IC50 (µMol)10.00000.00100.33498.9000AID756116
Epoxide hydrolase 1 Homo sapiens (human)IC50 (µMol)10.00000.04002.98007.0000AID1373464
Liver carboxylesterase 1Homo sapiens (human)IC50 (µMol)10.00000.00400.25510.6000AID1373465
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)0.00090.00000.54509.1000AID1373456; AID1373458; AID1650817; AID1674906; AID1857694; AID756127
Bifunctional epoxide hydrolase 2Homo sapiens (human)Ki0.15600.00150.04540.1560AID1373462
Bifunctional epoxide hydrolase 2Mus musculus (house mouse)IC50 (µMol)10.00000.00170.05670.4220AID1373469
Epoxide hydrolase BMycobacterium tuberculosis CDC1551IC50 (µMol)12.10000.01900.66403.4000AID1798579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (76)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
prostaglandin metabolic processCocaine esteraseHomo sapiens (human)
xenobiotic metabolic processCocaine esteraseHomo sapiens (human)
catabolic processCocaine esteraseHomo sapiens (human)
apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
activation of adenylate cyclase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cell population proliferationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
Schwann cell developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
thyroid gland developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein-containing complex assemblyRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
somatic stem cell population maintenanceRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of Rho protein signal transductionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
response to muscle stretchRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
ERBB2-ERBB3 signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
wound healingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
myelinationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of MAPK cascadeRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
type B pancreatic cell proliferationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
intermediate filament cytoskeleton organizationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell differentiationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
thymus developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
face developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
type II interferon-mediated signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
death-inducing signaling complex assemblyRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell motilityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
MAPK cascadeRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
xenobiotic metabolic processEpoxide hydrolase 1 Homo sapiens (human)
response to toxic substanceEpoxide hydrolase 1 Homo sapiens (human)
response to organic cyclic compoundEpoxide hydrolase 1 Homo sapiens (human)
arachidonic acid metabolic processEpoxide hydrolase 1 Homo sapiens (human)
catabolic processEpoxide hydrolase 1 Homo sapiens (human)
epoxide metabolic processEpoxide hydrolase 1 Homo sapiens (human)
lipid metabolic processArylacetamide deacetylaseHomo sapiens (human)
xenobiotic metabolic processArylacetamide deacetylaseHomo sapiens (human)
positive regulation of triglyceride catabolic processArylacetamide deacetylaseHomo sapiens (human)
cholesterol biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
response to toxic substanceLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxLiver carboxylesterase 1Homo sapiens (human)
negative regulation of cholesterol storageLiver carboxylesterase 1Homo sapiens (human)
epithelial cell differentiationLiver carboxylesterase 1Homo sapiens (human)
cholesterol homeostasisLiver carboxylesterase 1Homo sapiens (human)
reverse cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
medium-chain fatty acid metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to cholesterolLiver carboxylesterase 1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusLiver carboxylesterase 1Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid secretionLiver carboxylesterase 1Homo sapiens (human)
lipid catabolic processLiver carboxylesterase 1Homo sapiens (human)
negative regulation of plasma lipoprotein oxidationSerum paraoxonase/arylesterase 1Homo sapiens (human)
cholesterol metabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
response to toxic substanceSerum paraoxonase/arylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxSerum paraoxonase/arylesterase 1Homo sapiens (human)
carboxylic acid catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
organophosphate catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
phosphatidylcholine metabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
lactone catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
lactone catabolic processSerum paraoxonase/arylesterase 2Homo sapiens (human)
response to toxic substanceSerum paraoxonase/arylesterase 2Homo sapiens (human)
renal sodium ion transportSerum paraoxonase/lactonase 3Homo sapiens (human)
negative regulation of superoxide anion generationSerum paraoxonase/lactonase 3Homo sapiens (human)
carboxylic acid catabolic processSerum paraoxonase/lactonase 3Homo sapiens (human)
establishment of localization in cellSerum paraoxonase/lactonase 3Homo sapiens (human)
lactone catabolic processSerum paraoxonase/lactonase 3Homo sapiens (human)
regulation of cellular response to drugSerum paraoxonase/lactonase 3Homo sapiens (human)
response to toxic substanceSerum paraoxonase/lactonase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityCocaine esteraseHomo sapiens (human)
carboxylesterase activityCocaine esteraseHomo sapiens (human)
carboxylic ester hydrolase activityCocaine esteraseHomo sapiens (human)
small GTPase bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
enzyme bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
identical protein bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
metal ion bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
MAP kinase kinase kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
epoxide hydrolase activityEpoxide hydrolase 1 Homo sapiens (human)
protein bindingEpoxide hydrolase 1 Homo sapiens (human)
oxysterol bindingEpoxide hydrolase 1 Homo sapiens (human)
cis-stilbene-oxide hydrolase activityEpoxide hydrolase 1 Homo sapiens (human)
catalytic activityArylacetamide deacetylaseHomo sapiens (human)
triglyceride lipase activityArylacetamide deacetylaseHomo sapiens (human)
protein bindingArylacetamide deacetylaseHomo sapiens (human)
lipase activityArylacetamide deacetylaseHomo sapiens (human)
serine hydrolase activityArylacetamide deacetylaseHomo sapiens (human)
deacetylase activityArylacetamide deacetylaseHomo sapiens (human)
sterol esterase activityLiver carboxylesterase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylesterase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityLiver carboxylesterase 1Homo sapiens (human)
aryldialkylphosphatase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
arylesterase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
calcium ion bindingSerum paraoxonase/arylesterase 1Homo sapiens (human)
phospholipid bindingSerum paraoxonase/arylesterase 1Homo sapiens (human)
protein homodimerization activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
acyl-L-homoserine-lactone lactonohydrolase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activitySerum paraoxonase/arylesterase 2Homo sapiens (human)
metal ion bindingSerum paraoxonase/arylesterase 2Homo sapiens (human)
acyl-L-homoserine-lactone lactonohydrolase activitySerum paraoxonase/arylesterase 2Homo sapiens (human)
arylesterase activitySerum paraoxonase/arylesterase 2Homo sapiens (human)
aryldialkylphosphatase activitySerum paraoxonase/lactonase 3Homo sapiens (human)
arylesterase activitySerum paraoxonase/lactonase 3Homo sapiens (human)
protein homodimerization activitySerum paraoxonase/lactonase 3Homo sapiens (human)
metal ion bindingSerum paraoxonase/lactonase 3Homo sapiens (human)
acyl-L-homoserine-lactone lactonohydrolase activitySerum paraoxonase/lactonase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
endoplasmic reticulumCocaine esteraseHomo sapiens (human)
endoplasmic reticulum lumenCocaine esteraseHomo sapiens (human)
intracellular membrane-bounded organelleCocaine esteraseHomo sapiens (human)
plasma membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
nucleusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
mitochondrial outer membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
Golgi apparatusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
plasma membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
pseudopodiumRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
mitochondrionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
endoplasmic reticulum membraneEpoxide hydrolase 1 Homo sapiens (human)
endoplasmic reticulum membraneArylacetamide deacetylaseHomo sapiens (human)
endoplasmic reticulum membraneArylacetamide deacetylaseHomo sapiens (human)
cytoplasmLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulum lumenLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
cytosolLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
extracellular regionSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular spaceSerum paraoxonase/arylesterase 1Homo sapiens (human)
endoplasmic reticulum membraneSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular exosomeSerum paraoxonase/arylesterase 1Homo sapiens (human)
blood microparticleSerum paraoxonase/arylesterase 1Homo sapiens (human)
high-density lipoprotein particleSerum paraoxonase/arylesterase 1Homo sapiens (human)
spherical high-density lipoprotein particleSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular spaceSerum paraoxonase/arylesterase 1Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular regionSerum paraoxonase/arylesterase 2Homo sapiens (human)
plasma membraneSerum paraoxonase/arylesterase 2Homo sapiens (human)
extracellular regionSerum paraoxonase/lactonase 3Homo sapiens (human)
endoplasmic reticulum membraneSerum paraoxonase/lactonase 3Homo sapiens (human)
extracellular exosomeSerum paraoxonase/lactonase 3Homo sapiens (human)
extracellular spaceSerum paraoxonase/lactonase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (60)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1373457Inhibition of human FAAH2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID756113Cytotoxicity against human HuH7 cells by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1674904Solubility of the compound in 0.1 M sodium phosphate buffer at pH 7.42020Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18
Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors.
AID1650817Inhibition of human soluble epoxide hydrolase using CMNPC as substrate by fluorescence based assay2020Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility.
AID756122Inhibition of recombinant MET (unknown origin) at 10 uM2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1373463Competitive inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction assessed as increase in substrate Km using varying CMNPC substrate levels by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID756119Inhibition of recombinant PDGFRalpha (unknown origin) at 10 uM2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID756118Inhibition of recombinant KDR (unknown origin) at 10 uM2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1373471Inhibition of FAAH in mouse brain microsomes using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID756112Antiproliferative activity against HUVEC after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1373456Inhibition of soluble epoxide hydrolase (unknown origin)2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373470Inhibition of AADAC (unknown origin) expressed in baculovirus system using CMNA substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID756124Inhibition of recombinant FLT-1 (unknown origin) at 10 uM2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1373474Inhibition of FAAH in dog brain microsomes using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID756116Inhibition of full length recombinant c-RAF (unknown origin) using MEK1 as substrate after 1 hr by luminescence assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID756127Inhibition of human recombinant soluble epoxide hydrolase assessed as cyano(6-methoxy-naphthalen-2-yl)methyl trans-[(3-phenyloxyran-2-yl)methyl] carbonate conversion to 6-methoxy-2-naphthaldehyde preincubated for 5 mins prior to substrate addition by fluo2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1186230Inhibition of human recombinant soluble epoxide hydrolase assessed as half-life of enzyme-inhibitor complex by FRET-based ACPU displacement assay2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
AID1650815Aqueous solubility of compound2020Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility.
AID756126Inhibition of recombinant ABL-2 (unknown origin) at 10 uM2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1691499Inhibition of human mEH at 50 uM using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay relative to control2020European journal of medicinal chemistry, May-01, Volume: 193Development of potent inhibitors of the human microsomal epoxide hydrolase.
AID1373473Inhibition of FAAH in cat brain microsomes using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID756123Inhibition of recombinant FGFR-2 (unknown origin) at 10 uM2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1373477Inhibition of soluble epoxide in rat brain microsomes using CMNPC substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373476Inhibition of soluble epoxide in mouse brain microsomes using CMNPC substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1674906Inhibition of recombinant human soluble epoxide hydrolase using CMNPC as fluorescent substrate2020Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18
Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors.
AID1373468Inhibition of PON2 (unknown origin) expressed in baculovirus system using CMNA substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373462Competitive inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction using varying CMNPC substrate levels by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373464Inhibition of microsomal epoxide hydrolase (unknown origin) expressed in baculovirus system using CMNMC substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373479Inhibition of soluble epoxide in dog brain microsomes using CMNPC substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373467Inhibition of PON1 (unknown origin) expressed in baculovirus system using CMNA substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373480Inhibition of soluble epoxide in horse brain microsomes using CMNPC substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373460Time dependent inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction pre-incubated for 10 to 70 mins before CMNPC substrate addition by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373478Inhibition of soluble epoxide in cat brain microsomes using CMNPC substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID756121Inhibition of recombinant GSK3alpha (unknown origin) at 10 uM2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID756114Cytotoxicity against human HepG2 cells by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID756117Inhibition of recombinant PDPK-1 (unknown origin) at 10 uM2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1373459Inhibition of human FAAH expressed in baculovirus-infected High Five cells S9 fraction using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373465Inhibition of human carboxylesterase 1 expressed in baculovirus system using CMNA substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373466Inhibition of human carboxylesterase 2 expressed in baculovirus system using CMNA substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373458Inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction using CMNPC substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID756120Inhibition of recombinant PDGFRbeta (unknown origin) at 10 uM2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1373472Inhibition of FAAH in rat brain microsomes using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1857694Inhibition of human recombinant sEH2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors.
AID756125Inhibition of recombinant FLT-3 (unknown origin) at 10 uM2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
AID1373469Inhibition of PON3 (unknown origin) expressed in baculovirus system using CMNA substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1373475Inhibition of FAAH in horse brain microsomes using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1798579Mtb EHB Inhibition Assay from Article 10.1016/j.jmb.2008.06.030: \\The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.\\2008Journal of molecular biology, Sep-12, Volume: 381, Issue:4
The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's6 (46.15)24.3611
2020's5 (38.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.27 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]